Table 1.
Studies that investigated the clearance of RAS mutations in the plasma of metastatic colorectal cancer patients at the time of progression of disease.
| References | N patients | ctDNA assay used | Patients with clearance of RAS mutations in plasma at PD (%) |
Patients with confirmed ctDNA presence in plasma
at PD (%) |
Method to confirm
ctDNA presence |
|---|---|---|---|---|---|
| Raimondi et al. (3) | 11 | Idylla | 5/11 (45%) | 1/7 (14%) | NGS |
| Moati et al. (4) | 36 | ddPCR/NGS | 8/36 (22%) | 2/30 (6.6%) | Methylation test |
| Fernández Montes et al. (9) | 15 | Not specified | 2/15 (13%) | 2/15 (13%) | Not specified |